Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers

GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro

(2010) Szabolcs Bellyei et al.   CANCER LETTERS

Bevacizumab toxicities and their management in ovarian cancer

(2010) Leslie M. Randall et al.   GYNECOLOGIC ONCOLOGY

The effect of GHRH antagonists on human glioblastomas and their mechanism of action

(2010) Eva Pozsgai et al.   INTERNATIONAL JOURNAL OF CANCER

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY

Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138

(2008) Elmar Heinrich et al.   PROSTATE

Angiogenesis as a strategic target for ovarian cancer therapy

(2008) Whitney A Spannuth et al.   Nature clinical practice. Oncology

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

(2007) Andrew V Schally et al.   Nature clinical practice. Endocrinology & metabolism